Mode
Text Size
Log in / Sign up

ACIP Recommends JYNNEOS Vaccine for Occupational Orthopoxvirus Exposure RiskU.S. health advisors recommend monkeypox vaccine for certain at-risk workers

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider ACIP recommendation for JYNNEOS in occupational orthopoxvirus risk; refer to full guidance.

This is a recommendation report from the Advisory Committee on Immunization Practices (ACIP) regarding the use of the JYNNEOS vaccine for persons at risk of occupational exposure to orthopoxviruses, including smallpox, monkeypox, and cowpox, in the United States. The document recommends JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for preexposure vaccination in this population. The ACIP issued this recommendation in 2021.

No study results, efficacy data, or safety outcomes are reported within this document. The report does not provide information on adverse events, serious adverse events, discontinuations, or tolerability. Sample size, follow-up duration, and comparator groups are not applicable as this is not a research study.

Key limitations stem from the document's nature as a recommendation rather than an evidence-generating study. It does not present new clinical trial or observational data to support the recommendation's underlying evidence base. Funding sources and potential conflicts of interest are not reported.

For clinical practice, this report signals official ACIP guidance for considering preexposure vaccination with JYNNEOS in specific occupational settings. Healthcare providers managing workers at risk for orthopoxvirus exposure should consult the complete ACIP recommendations and relevant clinical guidelines for detailed implementation criteria, which are not specified in this summary.

A U.S. health advisory committee has issued a formal recommendation for the JYNNEOS vaccine. They say it should be offered to people whose jobs put them at risk of exposure to orthopoxviruses, which include monkeypox, smallpox, and cowpox. This applies to certain laboratory workers and healthcare professionals who might handle these viruses.

This document is a recommendation from the Advisory Committee on Immunization Practices (ACIP), which helps guide U.S. vaccination policy. It is not a new research study. The recommendation itself does not contain new data on how effective the vaccine is for these workers or detailed information about its safety in this specific group.

The main reason to be careful is that this is a policy recommendation, not proof from a fresh study. It is based on the committee's review of existing evidence and their judgment of the potential risk to these workers. Readers should understand this as official guidance for doctors and public health officials on who should be offered this vaccine for prevention, not as a report of new scientific findings.

What this means for you:
Health officials recommend a preventive vaccine for workers at risk of exposure to viruses like monkeypox.

Study Details

EvidenceLevel 5
PublishedJun 2022
View Original Abstract ↓
This report describes ACIP's 2021 vaccine recommendation, JYNNEOS, against orthopoxviruses such as smallpox, monkeypox, and cowpox.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.